poisar

Stocks · News reference

Palisade Bio Reports Third Quarter 2026 Financial Results and Provides Business Update

Fiscal.ai

Palisade Bio announced its financial results for the third quarter ended September 30, 2026, and provided updates on its clinical development programs for PALI-2108.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. SEC EDGARSEC EDGAR

    8-K filing — PALISADE BIO, INC. (PALI)

    Filed: 2026-11-10 AccNo: 0001357459-26-000025 Size: 639 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

  2. BenzingaBenzinga Newsdesk

    Palisade Bio Announces Findings Presented At United European Gastroenterology Week; Five-Patient Phase 1B Crohn’s Disease Cohort Showed 47.5% Reduction In Mean Endoscopic Disease Activity And 58.8% Reduction In Mean Fecal Calprotectin After 14 Days; Phase 2b ASCENTRA-UC Study Is Enrolling; Phase 2a Crohn’s Disease Study Being Initiated

    linical and translational findings presented in one oral presentation and three moderated posters at United European Gastroenterology (UEG) Week 2026, held October 17–20 in Barcelona, Spain. The findings connect